productive Ocular, biopharma start of Ocular our stage very been of a the fully been company. has integrated quarter This a transition the highlight has into which commercial clearly, Donald. for of marks commercial DEXTENZA, launch Thanks, the
to now tell Commercial the in distributors. We is full are rollout. that product you DEXTENZA at pleased is
Our been field and force is has on calling since trained accounts May.
surgeons a with staff. a DEXTENZA And has the for Our supply program migration have in ourselves position begun. well and we to the patients, been We believe by best received sampling has that commercial put launch. successful their
patients launch: for quarter in reimbursement C-code for pain; and the Part B. CMS’ under DEXTENZA’s place early key one, treatment of of sNDA transitional of DEXTENZA issuance status FDA two, and our DEXTENZA which include support took Two label enables events inflammation approval to payment post-surgical Medicare broadens the to the pass-through a that covered
After ended, DEXTENZA, It CMS on active our October and for the J-code X year. that the J-code unique become [ophthalmic] products this important quarter like note our [ph] issued is a setting. status, to permanent only the is of the office it pass-through payment not given importance particular into proposition. also to it’s in and deployed HCPCS most value utilized can be DEXTENZA for
optimized. the while easily ophthalmic interest number in deliver this DEXTENZA significant treatment, DEXTENZA place, is steroid But inherent enjoy can expressed the a flexibility. physicians, J-code dropless who patients of in setting, office have the more benefits using of in had the so surgery You’ve fully on can
both approved deliver of intracanalicular pain. potential The for administration patients form to become transformative the has is for of may XX a insert DEXTENZA product dosage first is a those treatment be the to days. a of new dexamethasone product the bioresorbable, dose Ocular novel DEXTENZA in and For the and of preservative-free inflammation milligram physicians. to X.X to for post-surgical a route story, who up has
For under single topical require of regimen insert. to delivered of and a steroid ocular current a of a treatment complex care will steroid course XX eye in of the convenience means up offer drop This standard aggregate delivery the with full can can preservative-free full month. patients, DEXTENZA replace the drops over
For of regimen puts of control DEXTENZA steroid noncompliance. in the their by risk patient’s mitigating physicians, post-surgical hands back the
substantial. opportunity The steroid year. market written alone is each prescriptions X there are U.S. million for DEXTENZA In ocular the approximately
time. a delivering over the through is to Our and the eventual intend the all to compete programs that them. goal to of eye steroid of surface we demonstrate is for our better of DEXTENZA way management lifecycle
Given any are surgery, X insertion important million annually The commercial our code is also or this B. under is reliable to It to note DEXTENZA with future intracanalicular procedure drug-eluting of gain cataract associated CPT expectation performed procedures insert the time. other on usage is and over Part and more establish reimbursement current our code to XXXXT. efforts payment of initial that focused labeling focused on Medicare
Scott which a by our positive of centers part Senior surgeons experiences determine strategy, encouraged is continuing launch and on and to surgery will success launch staff DEXTENZA their stages, observed surgeon ASCs, protocol. enthusiasm more maximize patient, personally for will President, used be product. I with the clinically number since Our both In make the and of number key ambulatory go DEXTENZA, or but our administratively. the of Vice Commercial how not have to the the surgery early that many cataract DEXTENZA into shortly depth early Corning, designed the
relationships. DEXTENZA protocol that deep we that proper Making the of customer interesting services the build and required surgical standard and with part surround the we support
near-term remind provide While call. to Dr. our Goldstein, the our about driver Michael the important everyone is an clearly CMO it robust be for launch in later will pipeline. Ocular, this DEXTENZA value update of will
of of Operations Corporate good organization. and as Development launch Finally, to Officer of a Patricia development to as build Chris pipeline, with our programs; oversee we of we quarter, manufacturing In we talk Kitchen, White, the senior and top about all Business news DEXTENZA the Chief management the efforts. two associated continue this our quality and important announced our Head hires, and notch
people, to caliber the and volumes and platform. that attract the excited it is are culture team, Patricia Ocular of a the We the the speaks for potential and able of encouraged Chris,
that Senior introduction, for to Vice turn President, Scott call like commercial Corning, the I’d of over of Commercial to our our more With launch DEXTENZA.
